NASDAQ:CPRX

Catalyst Pharmaceuticals Stock News

etoro logo Buy CPRX
*Your capital is at risk
$31.49
+0 (+0%)
At Close: Jul 31, 2026
Inovalis REIT (TSX:INO.UN) is an example of one of many high-yield investments that can help Canadians supplement their OAS and CPP pensions.
You should invest in Emera Inc. for its defensive qualities because your retirement could be at risk after COVID-19.
The CPP enhancements should bear significance to CPP users with retirement anxiety due to the 2020 health crisis. You can supplement the pension with investment income from the BCE stock.
FGIC Announces NYSDFS Approval of CPP Upward Adjustment
Griffon Corporation (“Griffon” or the “Company”) (NYSE:GFF) today announced it will present at the Sidoti Fall 2020 Investor Conference on Thursday, S

Should You Start Your CPP Pension At 65 or 70?

12:49pm, Friday, 11'th Sep 2020
Choosing to start the CPP at 65 or 70 is a major decision for retiring Canadians. However, supplementing the pension with investment income from the Enbridge stock is a must to enjoy retirement.
Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and subsidiary of Purdue Pharma L.P., today announced results from two Phase 1b
Don’t depend on your CPP and OAS payments alone. A lot can change by the time you retire. Spread your bets and secure your finances with dividend stocks like TD Bank (TSX:TD)(NYSE:TD).
CORAL GABLES, Fla., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing i

5 Midcap Magic Formula Stocks For Total Return

01:12pm, Sunday, 16'th Aug 2020
Introduction To keep myself sharp and my skills honed, I routinely go to my library of investment books and re-read classics that have had an impact on me.  This week I did a complete re-read of Jo

ROCE Insights For Catalyst Pharmaceuticals

02:30pm, Friday, 14'th Aug 2020
Catalyst Pharmaceuticals (NASDAQ: CPRX) posted a 3.91% decrease in earnings from Q1. Sales, however, increased by 1.61% over the previous quarter to $29.61 million. Despite the increase in sales this
Shares of the rare-disease drugmaker Catalyst Pharmaceuticals (NASDAQ: CPRX) are under pressure Tuesday morning. Catalyst's stock is sinking in response to the news that the company's effort to expan
-The allowed claims are directed to methods of treating patients with a 3,4-DAP sensitive disease comprising administering 3,4-DAP or a salt thereof to slow acetylating patients having certain mutatio
Griffon Corporation (“Griffon” or the “Company”) (NYSE:GFF) announced today that it intends to offer and sell, subject to market and other conditions,
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE